Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15. (scientific article published on 13 November 2017)

Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins

Q24294612

Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc

Q27622123

Cetuximab for the treatment of colorectal cancer.

Q27851419

IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells

Q28214975

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

Q29619885

Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer

Q33418729

Adoptive cell transfer as personalized immunotherapy for human cancer

Q34043643

Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.

Q34205052

Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy

Q34533728

Dendritic cells prime natural killer cells by trans-presenting interleukin 15

Q36157184

Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor

Q36363861

Differential requirement for IL-2 and IL-15 during bifurcated development of thymic regulatory T cells

Q36838267

Interleukin-2 toxicity

Q37776348

Scavenger receptor class B, type I: a promising immunotherapy target.

Q37851971

Interleukin-15 in gene therapy of cancer.

Q38060229

Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.

Q38299799

Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa

Q38343329

The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas

Q38831202

Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.

Q39110347

Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency

Q39203683

Exploiting scavenger receptors in cancer immunotherapy: Lessons from CD5 and SR-B1.

Q39306589

NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.

Q40062910

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

Q45949257

Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.

Q46748932

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

Q69548004

The long signal peptide isoform and its alternative processing direct the intracellular trafficking of interleukin-15

Q73929921

P433

issue

P921

main subject

cetuximab

Q420296

P304

page(s)

e1393597

P577

publication date

2017-11-13

P1433

published in

OncoImmunology

Q18026500

P1476

title

Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15.

P478

volume

Reverse relations

cites work (P2860)

Q89997716	Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol
Q58561585	Cytokines in clinical cancer immunotherapy
Q92594689	Natural Killer Cells: Diverse Functions in Tumor Immunity and Defects in Pre-neoplastic and Neoplastic Stages of Tumorigenesis